MERCK KGAA

The global induced pluripotent stem cells (iPSCs) market, valued at USD 1.88 billion in 2023, is projected to grow to USD 4.48 billion by 2032, driven by advancements in regenerative and personalized medicine, drug discovery, and increased investments in stem cell research. Key market participants focus on improving iPSC generation methods, while challenges include high production costs, ethical issues, and regulatory complexities. North America leads the market, with Asia-Pacific showing rapid growth.

The global Head and Neck Cancer Diagnostics market is expected to grow from $6.8B in 2023 to $15.2B by 2030, driven by advancements in liquid biopsy, NGS, AI, and molecular testing. Rising cancer incidence, personalized medicine, and healthcare policies are key factors. The report offers detailed market analysis, competitive insights, and future trends.

Authors from various institutions collaborated on a project, with A.R.M.B. and M.F.E. as originators. Experimental work was conducted by C.L.L. and F.F., and data processing by M.F.E. and L.S. Additional contributors participated in experiments and manuscript editing.

Pyrogen Testing Market size is projected to reach USD 2.8 billion by 2032, driven by the expanding pharmaceutical and biotechnology industries. The rise in drug development and biologics manufacturing globally increases demand for pyrogen testing to ensure product safety. Advances in testing technologies, such as recombinant factor C (rFC) assays and in vitro methods, offer efficient, ethical, and cost-effective alternatives to traditional animal-based tests. The in vitro pyrogen test segment is expected to grow significantly due to its ethical and cost-effective advantages. Medical device companies also show strong demand for pyrogen testing to ensure device safety. Asia Pacific is anticipated to be a lucrative market, driven by expanding pharmaceutical industries in countries like China and India.

Patients are becoming active participants in clinical research. EUPATI educates patients, TransCelerate improves patient experience, and collaboration among stakeholders is crucial. The goal is a patient-centered system where patients contribute actively and investigational medicines are accessible.

MilliporeSigma, a Life Science business of Merck KGaA, announces a $76 million expansion of its ADC manufacturing capabilities in St. Louis, tripling capacity and enhancing its CDMO offering. This investment aims to accelerate drug development and bring novel therapies to market more quickly, focusing on targeted oncology treatments.

The global bioanalytical services market is expected to grow from $3,291.2 million in 2023 to $9,105.4 million by 2032, driven by increasing demand for bioanalytical support in drug development, technological advancements, and regulatory requirements. Key segments include small molecule bioanalysis, oncology, and cell-based assays, with leading companies such as Charles River Laboratories Inc. dominating the market.

The red biotechnology market is projected to grow from $509.71 billion in 2023 to $867.20 billion by 2028, driven by advancements in personalized medicine, biosimilars, and genetic engineering. Major players include Pfizer, Roche, Bayer, and Amgen.

The global biotechnology market, valued at USD 1.37 trillion in 2022, is projected to grow at a CAGR of 13.8% driven by technological advancements, increased R&D, and demand for innovative applications in healthcare and agriculture. Key technologies include 3D bioprinting, genomic analysis, fermentation, nanotechnology, and bioinformatics. Major players include AstraZeneca, Gilead Sciences, Novo Nordisk, Abbott Laboratories, Amgen, Thermo Fisher Scientific, Merck KgaA, Johnson & Johnson, Novartis, Hoffmann-La Roche, Pfizer, and Moderna. Challenges include high costs, regulatory constraints, and ethical considerations.

The Menopausal Hot Flashes Market report by DataM Intelligence analyzes market trends, key players (Pfizer Inc, AbbVie Inc., Bayer, etc.), and growth projections through 2024-2031. It highlights advancements in medical technologies and patient-centered care driving market growth, with regions including North America, Europe, Asia Pacific, and more covered. Key developments include Veozah's FDA approval and Elda Health's product launch.